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httpcense.Abstract Rationale: The impact of antituberculous treatment on (IFN)-c response to mycobacte-
rial tuberculosis antigens have been widely investigated but the results have been controversial.
Aim of work: To evaluate the role of Quantiferon TB gold assays as one of the interferon-gamma
release assays (IGRAs) for monitoring the efﬁcacy of antituberculosis therapy in patients with active
disease.
Subjects and methods: Thirty patients with active pulmonary TB were enrolled in this cross-sec-
tional study where they were subjected to history taking, clinical examination, chest X-ray, direct
smear examination of sputum samples for AFB using Ziehl–Neelson stain performed on three visits;
up on enrollment, 2 and 6 months later. Lowenstein Jensen medium cultures of sputum samples were
done for isolation of Mycobacterium tuberculosis on ﬁrst visit. All patients in the study group were
subjected to QuantiFERON-TB Gold estimation on the three visits.
Results: The mean sensitivity and speciﬁcity of QFT-G test was 85.9% and 62.6% respectively.
Using v2 analysis, there was a statistically signiﬁcant association between QFT-G results and culture
results upon enrollment and Acid fast bacilli positivity on second and third visits. Studying the
changes in QFT-G results throughout the whole study period revealed a statistically signiﬁcant
decrease in number of QFT-G positive cases from 24/29 patients (82.8%) at ﬁrst visit to 4/25 patients
(16%) at the third visit. All 21/25 patients (84%) who became QFT-G negative at the end of the study
had a complete clinical and microbiological recovery of the TB disease.
Conclusion: The analysis of QFT-G assay results showed that in the majority of our TB patients
there was a correlation between clinical treatment outcome and changes of IFN-c response to
M. tuberculosis-speciﬁc antigens.
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The immune response in tuberculosis (TB) plays a fundamen-
tal role in the outcome of Mycrobacterium tuberculosis infec-
tion. It is clear that the immune system reacts efﬁciently in
the vast majority of infections. This is particularly evident in
the case of TB, where most people infected by the tubercle
bacillus do not develop the disease throughout their lifetimes
[1]. Therefore, although the host cell-mediated immunity is en-
ough to control the progression of disease, it fails to exert ster-
ile eradication and hence, those two billion infected persons
suffer the latent form of TB [2].
As for other intracellular infections, the primary protective
immune response is cell mediated rather than antibody medi-
ated. M. tuberculosis resides inside the macrophage and is rel-
atively resistant to microbicidal mechanisms that efﬁciently
eliminate other phagocytosed bacteria. This is due in part to
the ability of the tubercle bacilli to hinder macrophage activa-
tion by IFN-c and IL-12. Several studies have conﬁrmed the
critical importance of these cytokines in both human and mice
M. tuberculosis infection. In addition, deﬁciencies in IL-12 or
IFN-c, or their receptors, render the individual more suscepti-
ble to mycobacterial infections [3,4].
Attempts have been made to exploit the T-cell response for
rapid diagnosis of M. tuberculosis infection, through the inter-
feron (IFN)-c assays. These assays are based on the fact that
T-cells sensitized with tuberculous antigens will produce
IFN-c when they are re-exposed to mycobacterial antigens.
A high amount of IFN-c production is then presumed to cor-
relate with TB infection [5].
The QuantiFERON-TB Gold test (QFT-G) is a whole-
blood test for use as an aid in diagnosingM. tuberculosis infec-
tion, including latent tuberculosis infection (LTBI) and tuber-
culosis (TB) disease. This test was approved by the US Food
and Drug Administration (FDA) in 2005 [6].
The ﬁrst IFN-assays made use of puriﬁed protein derivative
(PPD) as the stimulating antigen; more recent assays, use anti-
gens that are speciﬁc toM. tuberculosis, such as the early secre-
tory antigen target 6 (ESAT6), and the culture ﬁltrate protein
10 (CFP10), protein antigens are coded by genes located in the
region of difference l (RDl) of the M. tuberculosis genome and
are much more speciﬁc than PPD, since they are not shared
with Mycrobacterium bovis bacillus Calmette–Guerin (BCG)
or most nontuberculous mycobacteria (NTM) with the excep-
tion of Mycrobacterium marinum, Mycrobacterium sulzgai and
Mycrobacterium kansassi. Thus these tests provide an advanta-
geous alternative to tuberculin test with its false- positive re-
sults especially in BCG-vaccinated persons and in areas of
high incidence [5].
The QFT-Gold offers a number of advantages compared
with the TST, including increased speciﬁcity in persons who
have had a BCG vaccination, and elimination of the need
for a second visit to read the TST. Providers and facilities pro-
viding TB testing should determine if QFT-Gold will replace
the TST or will be used to conﬁrm positive TST results. Con-
siderations include cost, feasibility, TST reading rates, and
availability of the test. Maximum beneﬁt from QFT-Gold is
likely to be realized in BCG vaccinated individuals, popula-
tions with poor adherence rates to TST reading, and in settings
where quality assurance and training of skin testing is poor or
lacking [7].QFT-G, as with the TST, cannot differentiate infection asso-
ciatedwith TB disease fromLTBI. A diagnosis of LTBI requires
that TB disease be excluded by medical evaluation, which
should include checking for suggestive symptoms and signs, a
chest radiograph, and, when indicated, examination of sputum
or other clinical samples for the presence ofM. tuberculosis [8].
As with a negative TST result, negative QFT-G results should
not be used alone to exclude M. tuberculosis infection in persons
with symptoms or signs suggestive of TB disease. The presence
of symptoms or signs suggestive of TB disease increases the likeli-
hood that M. tuberculosis infection is present, and these circum-
stances decrease the predictive value of a negative QFT-G or
TST result. Medical evaluation of such persons should include a
history and physical examination, chest radiograph, bacteriologic
studies, serology for human immunodeﬁciency virus (HIV), and,
when indicated, other tests or studies [9].
IGRAs are dynamic and both conversions and reversions
occur when serial testing is done; this has been shown to occur
among contacts as well as health care workers. There is no
consensus on what the best deﬁnition for conversion is – differ-
ent deﬁnitions appear to produce different rates of conver-
sions. QFT reversions were deﬁned as baseline IFN-cP 0.35
and follow-up IFN-c< 0.35 IU/ml [10].
Some reversions may reﬂect clearing of TB infection (spon-
taneous or due to treatment). Some reversions may merely be
due to biological variations among IGRA positive individuals,
and some reversions may be due to variability in laboratory
and test procedures. Other studies suggested that IGRA re-
sponses are inherently transient and generally require contin-
ued exposure to TB antigens to maintain high frequencies.
They argue that reversions may simply reﬂect the life cycle
ofM. tuberculosis, where the mycobacterium enters a dormant
state in which it may not reliably secrete antigens such as early
secreted antigen target 6 (ESAT-6) and culture ﬁltrate protein
10 (CFP-10), but instead secrete other antigens (which are not
used in currently available IGRAs). Alternatively, ESAT-6
and CFP-10 may be secreted intermittently over the life cycle
of M. tuberculosis, which may partly explain the variations
over time. These hypotheses are worthy of further study [11].
Aim of work
This study was planned to evaluate the role of Quantiferon TB
gold assays as one of the interferon-gamma release assays
(IGRAs) for monitoring the efﬁcacy of antituberculosis ther-
apy in active tuberculous patients.
Subjects and methods
Thirty patients with active pulmonary TB were enrolled in this
cross-sectional study from August 2009 to February 2010, the
enrollment was carried out in OMRANYA Chest hospital.
Where active tuberculosis patients were admitted from the
out-patients clinic.
The participants consisted of 18 males and 12 females.
Exclusion criteria
– Debilitating diseases: diabetes, renal or hepatic impairment
or failure, acquired immune deﬁciency syndrome (AIDS).
– Extra-pulmonary tuberculosis.
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– Children.
All of the patients were subjected to
1- History including:
 Pulmonary questionnaire: where the patients were asked
about the following:
 Persistent productive cough, with or without hemptysis
 Breathlessness
 Weight loss
 Loss of appetite
 Fever; 38 C or above (night fever-night sweats
 Past history: of old TB infection.
2- Clinical examination:
 General examination
 Local examination
3- Laboratory: ESR: Erythrocyte sedimentation rate
4- Chest roentgenogram
5- Microbiology:
(A) Direct smear examination for AFB by Ziehl–Neelsen
stain:
At ﬁrst visit: up on enrollment.
2nd visit: 2 months later.
3rd visit: 6 months later.
(B) Culture medium for isolation of Mycobacterium tuber-
culosis (Lowenstein–Jensen medium) BBL
MycoPrep
All patients in the study group were subjected to culture
using Lowenstein–Jensen (L–J) medium at the time of
enrollment.
1- The Whole Blood IFN-gamma test, QuantiFERON-
TB Gold
All patients in the study group were subjected to Quanti-
FERON-TB Gold estimation:
At ﬁrst visit: up on enrollment.
2nd visit: 2 months later.
3rd visit: 6 months later.
The QuantiFERON-TB Gold In-Tube (IT) is an in vitro
diagnostic test using a peptide cocktail simulating ESAT-6,
CFP-10 and TB7.7 proteins to stimulate cells in heparinised
whole blood. Detection of interferon-c by Enzyme-Linked
Immunosorbent Assay (ELISA) is used to identify in vitro
responses to the peptide antigens that are associated with
M. tuberculosis infection.
N.B: Individuals infected with M. tuberculosis complex
organisms usually have lymphocytes in their blood that recog-
nise mycobacterial antigens (existed on the tubes wall). This
recognition process involves the generation and secretion of
the cytokine, IFN-c. The detection and subsequent quantiﬁca-
tion of IFN-c forms the basis of this test.
Contents of the Quantiferon TB-G-It packet: cellestis limited
(Australia) and cellestis Inc., (package insert, 2006)
Tuberculosis and control antigen blood collection tubes1. Nil control (Grey cap).
2. TB antigen (Red cap).
3. Mitogen control (Purple cap) – did not used in this study.
ELISA Components in the packet:
1. Microplate strips: Containing the ELISA wells.
2. Human IFN-c Standard, lyophilized: For preparation of
fresh dilutions of the kit standard for each ELISA ses-
sion as a control before calculation of the results.
3. Green diluent. (GD): Share in the kit dilutions.
4. Conjugate 100X Concentrate, lyophilized: A conjugated
monoclonal antibody to IFN-c, this is an enzyme linked
antibody that mixed with the infected plasma samples.
5. Wash Buffer 20X Concentrate:For removal of the excess
non-mixing materials.
6. Enzyme Substrate Solution: When added to conjugate, it
achieves color that indicates positivity.
7. Enzyme stopping solution: Finally, added to halt the
reaction.N.B: The non visible reaction between the plasma samples
and the conjugate shows a colored visible reaction after adding
the enzyme substrate that indicates INF-c existence in the pa-
tient plasma sample
Calculations and test interpretation
The software performs a quality control assessment of the as-
say, generates a standard curve and provides a test result for
each subject as negative or positive through:
1. These calculations can be performed using software pack-
ages available with microplate readers, and standard
spreadsheet or statistical software (such as Microsoft
Excel).
2. Construct a log(e)–log(e) standard curve by plotting the
log(e) of the mean OD (y-axis) against the log(e) of the
IFN-c concentration of the standards in IU/mL (x-axis).
3. Use the standard curve to determine the IFN-c concentra-
tion (IU/mL) for each of the test plasma samples, using the
OD value of each sample.
The software performs a quality control assessment of the
assay, generates a standard curve and provides a test result
for each subject as negative or positive.
Gender
60%
40%
Male Female
 
Figure 1 Pie chart representing gender distribution among the
studied group.
Culture
76%
24%
Positive Negative
Figure 2 Pie chart representing culture results at ﬁrst visit.
Table 1 Frequency and percentages of Quantiferon test
results in the ﬁrst visit.
Visit Quantiferon Freq. %
First visit (on admission) Positive 24 82.8
Negative 5 17.2
Total 29 100
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This study was conducted on 30 cases; 18 males and 12 fe-
males. Their ages ranged between 17 and 87 years (mean ±
SD= 38 ± 20.2)
Statistical analysis
Qualitative data were presented as frequencies and percent-
ages. v2 (x2) test was used for studying the association between
Quantiferon with AFB and Quantiferon with culture results.
Quantitative data were presented as minimum, maximum,
means and standard deviation (SD) values.
Sensitivity, speciﬁcity and diagnostic accuracy of Quantifer-
on were calculated as follows:
Sensitivity ð%Þ ¼ True positive
True positiveþ False negative  100
Specificity ð%Þ ¼ True negative
False positiveþ True negative  100
Diagnostic accuracyð%Þ ¼ True positiveþ True negative
Total number
 100
An increase in sensitivity means a decrease in false negative
cases, while an increase in speciﬁcity means a decrease in false
positive cases.
The signiﬁcance level was set at P 6 0.05. Statistical analy-
sis was performed with SPSS 16.0 (Statistical Package for
Scientiﬁc Studies) for Windows.
Quantiferon, ZN and culture results in ﬁrst visit
Culture. At ﬁrst visit, 1 case was excluded. Twenty-two sub-
jects (75.9%) showed positive culture and 7 subjects (24.1%)
showed negative culture.
Acid fast bacilli. At ﬁrst visit, 1 case was excluded. All cases (29
cases) showed positive Z–N.
Quantiferon. At ﬁrst visit, 1 case was excluded. Twenty-four
subjects (82.8%) showed positive Quantiferon test and ﬁve
subjects (17.2%) showed negative test.
There was a statistically signiﬁcant association between
Quantiferon and culture (P-value = 0.001). Twenty-one cases(95.5%) with positive culture showed positive Quantiferon.
Four cases (57.1%) with negative culture showed negative
Quantiferon.
Quantiferon and ZN results in second visit. There was a statis-
tically signiﬁcant association between Quantiferon and AFB
(P-value < 0.001). Three cases (100%) with positive AFB
showed positive Quantiferon. Twenty-three cases (95.8%) with
negative AFB showed negative Quantiferon.
Quantiferon and ZN results in third visit. There was a statisti-
cally signiﬁcant association between Quantiferon and AFB
(P-value < 0.001). Three cases (75%) with positive AFB
showed positive Quantiferon. Twenty cases (95.2%) with neg-
ative AFB showed negative Quantiferon (see Fig. 1).
Discussion
Monitoring the efﬁcacy of anti-TB therapy is crucial for the
better control of the spread of MTB infection; IGRAs are no-
vel indirect blood tests for M. tuberculosis infection and a
promising marker of mycobacterial burden and disease
activity.
Our study shows that the pattern of changes in IFN-c re-
sponses with treatment is highly signiﬁcant; the results of
QFT G IT test correlate with results of the microbiologic
sputum smear, culture and clinical outcome. The progressive
decline of (IFN)-c response measured by QFT G IT test
reﬂects the reduction of mycobacterial burden following a
successful anti-tuberculous treatment.
At the ﬁrst visit, Fig. 2 shows the correlation between the
culture and AFB results, one case was excluded (Deviations
from the procedure described in the Package Insert). All cases
were microbiologically AFB smear conﬁrmed, however, 22
subjects (75.9%) showed positive culture while seven subjects
Figure 3 Bar chart representing the association between culture and Quantiferon test at ﬁrst visit.
Table 2 Accuracy measures of Quantiferon compared to Z–N
at ﬁrst visit.
Z–N Positive Negative Total
Freq. Freq.
Quantiferon
Positive 24 0 24
Negative 5 0 5
Total 29 0 29
Table 3 Statistical comparison between Quantiferon and
culture results at ﬁrst visit.
Culture Positive (n= 22) Negative (n= 7) P-value
Freq. % Freq. %
Quantiferon
Positive (n= 24) 21 95.5 3 42.9 0.001*
Negative (n= 5) 1 4.5 4 57.1
* Signiﬁcant at P 6 0.05.
Table 4 Statistical comparison between Quantiferon and
AFB results at second visit using v2 test.
AFB Positive (n= 3) Negative (n= 24) P-value
Freq. % Freq. %
Quantiferon
Positive (n= 4) 3 100 1 4.2 <0.001*
Negative (n= 23) 0 0 23 95.8
* Signiﬁcant at P 6 0.05.
Role of Quantiferon TB gold assays in monitoring the efﬁcacy of antituberculosis therapy 333(24.1%) showed negative culture, the later could be due to
either harsh decontamination of the specimen or MOTT
(mycobacteria other than tuberculosis). Clinically, most pa-
tients with MOTT infections are initially suspected to have
M. tuberculosis and managed as such. In our study, we did
not add NAD+ or NADP+ to L–J medium during culture
preparations, thus we did not conﬁrm presence of MOTT in
cultures of our patients with sputum positive smear.
Regarding the Quantiferon results in the ﬁrst visit Table 1,
24 subjects (82.8%) showed positive Quantiferon test and ﬁve
subjects (17.2%) showed negative results. Todd [12] explained
why negative QuantiFERON-TB Gold IT result does not
preclude the possibility ofM. tuberculosis infection or tubercu-
losis disease; false-negative results could be due to stage of
infection (e.g., specimen obtained prior to the development
of cellular immune response), co-morbid conditions which af-
fect immune functions, incorrect handling of the blood collec-
tion tubes following veni-puncture, incorrect performance ofthe assay, or other immunological variables (see Fig. 3 and
Table 2).
Table 3 evaluated the association between Quantiferon
and culture results at ﬁrst visit, in which there was a statis-
tically signiﬁcant association between Quantiferon and cul-
ture (P-value = 0.001). The table showed one positive
culture patient with negative Quantiferon result. Kobashi
et al. [13] pointed out that this may be due to the decrease
of interferon-gamma production due to advanced patient age
or lymphocytopenia. The table also showed three subjects
with negative culture who gave positive QFT-G-IT re-
sponses, these discordant results in culture reaction could
be due to either too harsh decontamination or unequal dis-
tribution of the bacilli in the specimen during the culture
procedures (see Table 4).
In Table and Fig. 4, there was a statistically signiﬁcant asso-
ciation between Quantiferon and AFB (P-value < 0.001) in
the second visit. Three cases (100%) with positive AFB showed
positive Quantiferon. Twenty-three cases (95.8%) with nega-
tive AFB showed negative Quantiferon.
The results showed non conversion of positive sputum
smears in three subjects at the end of two months of treatment.
Kuaban et al. [14] studied the non conversion of sputum
smears at 2 months of treatment and found that it is signiﬁ-
cantly associated with age above or equal to 40 years and the
presence of numerous bacilli (3+) on pre-treatment sputum
smears. Patients with these factors who do not smear convert
after two months of treatment should be given a fully super-
vised treatment for the entire duration of therapy so as to pre-
vent in particular treatment default.
Figure 4 Bar chart representing the association between AFB and Quantiferon test at second visit.
Table 5 Accuracy measures of Quantiferon compared to AFB
at second visit.
AFB Positive Negative Total
Freq. Freq.
Quantiferon
Positive 3 1 4
Negative 0 23 23
Total 3 24 27
Sensitivity (%) = 100%, speciﬁcity (%) = 95.8.
Diagnostic accuracy (%) = 96.3%.
Table 6 Statistical comparison between Quantiferon and
AFB results at third visit using v2 test.
AFB Positive (n= 4) Negative (n= 21) P-value
Freq. % Freq. %
Quantiferon
Positive (n= 4) 3 75 1 4.8 <0.001*
Negative (n= 21) 1 25 20 95.2
* Signiﬁcant at P 6 0.05.
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Quantiferon result in spite of the conversion of the sputum
from positive to negative.
Katiyar et al. [15] attributed the reasons of why immune
responses to even speciﬁc antigens (ESAT-6 and CFP-10)
may not have dropped below the pre-deﬁned level of a positive
test after anti-tuberculosis treatment to exposure to environ-
mental mycobacteria commonly encountered in the tropics,
some of which share the ESAT-6 and CFP-10 genes. Sallakci
et al. [16] also suggested that may be there is inter-individualvariation in the strength of IFN-c response that can be partly
explained by genetic polymorphisms in the host.
When we evaluated patients’ sensitivity and speciﬁcity dur-
ing treatment in the second visit as shown in Table 5, the spec-
iﬁcity of QFN-G-IT was 95% and the sensitivity was 100%.
We set out to compare the association between Quantiferon
and AFB results at third visit as shown in Table 6 and Fig. 5
and found a statistically signiﬁcant association between Quan-
tiferon and AFB (P-value < 0.001). Three cases (75%) with
positive AFB showed positive Quantiferon. Twenty cases
(95.2%) with negative AFB showed negative Quantiferon.
The table pointed out to two cases; one of them showed posi-
tive Quantiferon with negative AFB result and was considered
to be a False positive result of Quantiferon test. The other
case, showed positive AFB and negative Quantiferon high-
lighting the fact that not all positive AFB smears areM. tuber-
culosis but could also be MOTT and again emphasizing the
role of cultures to accurately diagnose pulmonary TB and dif-
ferentiate Typical from Atypical Tuberculous infection.
Regarding the QFT-G assay sensitivity and speciﬁcity in
the third visit as shown in Table 7, the speciﬁcity QFN-G-IT
decreased from 100% to 75%, and the sensitivity almost con-
stant (95% and 95.2%) respectively.
In Table 8 we discussed the change by time in Quantiferon
results over the three visits. There was a statistically signiﬁcant
decrease in number of positive cases at second visit and com-
paring the results of the ﬁrst visit to third visit after 6 months
(end of the study period), there was a statistically signiﬁcant
decrease in number of QFT-G positive cases from 24/29 pa-
tients (82.8%) to 4/25 patients (16%) respectively. All 21/25
patients (84%) who became QFT-G negative at the end of
the study had a complete clinical and microbiological recovery
of the TB disease.
According to Hill et al. [11], T cell responses, especially
weakly positive responses, tend to ﬂuctuate over time, even
in the absence of speciﬁc treatment.
Carrara et al. [17], showed that an in vitro immune diagnos-
tic assay based on the response to ESAT-6-multiepitopic pep-
tides can be detected in patients who do not respond to
therapy. A possible explanation is that secretion ofM. tubercu-
Figure 5 Bar chart representing the association between AFB and Quantiferon test at third visit.
Table 7 Accuracy measures of Quantiferon compared to AFB
at third visit.
AFB Positive Negative Total
Freq. Freq.
Quantiferon
Positive 3 1 4
Negative 1 20 21
Total 4 21 25
Sensitivity (%) = 75% speciﬁcity (%) = 95.2%.
Diagnostic accuracy (%) = 92%.
Table 8 Statistical analysis showing the changes in Quanti-
feron test by time using McNemar’s test.
Visit Quantiferon Freq. %
First visit (on admission) Positive 24 82.8
Negative 5 17.2
Total 29 100
Second visit (2 months) Positive 4 14.8
Negative 23 85.2
Total 27 100
Third visit (6 months) Positive 4 16
Negative 21 84
Total 25 100
First visit vs. second visit P-value <0.001*
Second visit vs. third visit P-value 0.857
First visit vs. third visit P-value <0.001*
* Signiﬁcant at P 6 0.05.
Table 9 The mean Quantiferon sensitivity and speciﬁcity of
the three visits.
1st visit 2nd visit 3rd visit Mean
Sensitivity 82.8 100 75 85.9
Speciﬁcity Not computed 95.8 92 62.6
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active and viable bacilli and, thus, IFN-g-producing T cells
speciﬁc for ESAT-6 selected epitopes are present at highfrequency during the active phase of bacterial replication. It
has been shown that these T cells are pre-activated in vivo
and capable of rapid effector function. However, after receipt
of efﬁcacious therapy,M. tuberculosis stops replicating actively
and the frequency of the T cells speciﬁc for these epitopes dra-
matically decreases and, thus, is not detected by this assay.
However, the memory response to the whole ESAT-6 protein
remains.
It has been suggested by Leyten et al. [18] that the short
period of incubation (16–24 h), commonly used in IGRAs, de-
tects responses of activated effector T cells that rapidly release
IFN-c when stimulated in vitro with antigen. Kaech et al. [19]
conﬁrmed that long-lived central memory T cells that may be
less likely to release IFN-c during the short period of exposure
to antigen in the IGRA assay, could be detected after a longer
period of in vitro stimulation. Since the effector response is
driven by the antigen load, it was thought by Lalvani [20] that
the presence of active mycobacterial replication (active un-
treated TB) is associated with increasing of the numbers of
effector T cells. In the context of a low antigenic load, as in
successfully treated patients, the number of effector cells spe-
ciﬁc to M. tuberculosis antigen could fall below the cut-off
level.
According to Table 9 the mean sensitivity of QFT-TB test
in our study was 85.9% while the mean speciﬁcity was
62.6%. This data are in agreement with previous studies that
reported an excellent degree of sensitivity and speciﬁcity of
the QFT-TB test for diagnosis of active TB. Kobashi et al.
[13] concluded that the QFT-TB test had a mean sensitivity
of 86% and a mean speciﬁcity of 94%. They showed that
336 N. Helmy et al.Quantiferon test results concerning patients with active TB
transiently, decreased during treatment involving anti-tubercu-
lous drugs. The rate of positive QFT-TB test results was 86%
at the initiation of treatment, 48% six months later, and 33%
12 months later. Kang et al. [21] reported 81% sensitivity
among 54 patients, and Mori et al. [6] reported 89% sensitivity
among 118 patients.
In conclusion,
the results analysis of QFT-G assay showed that in the
majority of our TB patients there was a correlation between
clinical treatment outcome and changes of IFN-c response to
M. tuberculosis-speciﬁc antigens. Indeed, for all patients who
had a complete resolution of clinical disease and whose micro-
biological results were negative for M. tuberculosis at 6-month
treatment completion, a progressive decline of IFN-c release
was seen and the baseline positive QFT-G result had turned
negative.
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